Medivation’s Drug for Stubborn Cancers Raises Its Allure

  • Xtandi’s U.S. sales rose to more than $1 billion in 2015
  • Shared sales, thin pipeline haven’t deterred Sanofi interest

A drug called Xtandi that’s helping men fight hard-to-treat prostate cancers is luring a big drugmaker to its manufacturer, Medivation Inc.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.